Related Experiment Videos

DNA replication of first-generation adenovirus vectors in tumor cells

D S Steinwaerder1, C A Carlson, A Lieber

  • 1Division of Medical Genetics, University of Washington, Seattle, WA 98195, USA.

Human Gene Therapy
|September 15, 2000
PubMed

Insights

First-generation adenovirus vectors (AdE1(-)) replication depends on cell cycling, not tumor suppressor gene status. Viral DNA synthesis is enhanced when cells pass through G(2)/M, impacting tumor gene therapy.

Area of Science:

  • Virology
  • Molecular Biology
  • Oncology

Background:

  • Adenovirus early gene products E1A and E1B facilitate viral DNA replication by inactivating tumor suppressors like pRb and p53.
  • Tumor cells often exhibit deregulated p53 and pRb pathways, suggesting potential for replication of E1A/E1B-deleted adenovirus vectors (AdE1(-)).

Purpose of the Study:

  • To investigate the impact of virus uptake, cell cycling, and cell cycle regulators on AdE1(-) DNA synthesis in tumor cell lines.
  • To determine if deregulated tumor suppressor pathways influence AdE1(-) replication efficiency.

Main Methods:

  • Analyzed AdE1(-) vector internalization and nuclear import across various tumor cell lines.
  • Performed replication assays under equalized infection conditions.
  • Assessed the correlation between viral DNA replication and the status of p53, pRb, and p16.
  • Investigated the effect of cell cycle progression and G(2)/M arrest on AdE1(-) replication.

Main Results:

  • Tumor cell lines supported AdE1(-) synthesis to varying degrees, independent of p53, pRb, or p16 status.
  • Viral DNA replication efficiency was influenced by virus attachment and internalization, which varied with the cell cycle.
  • AdE1(-) infection induced a partial G(2)/M cell cycle arrest, enhancing vector DNA replication in arrested cells.

Conclusions:

  • Cell cycling, particularly passage through G(2)/M, supports AdE1(-) DNA replication in the absence of E1A/E1B.
  • Findings suggest cell cycle modulation could be a factor in the efficacy of first-generation adenovirus vectors for tumor gene therapy.

Related Concept Videos